AGO17 Antibody

What is ADAM17 and why are antibodies against it significant in research?

ADAM17, also known as TNF-alpha Convertase (TACE), was first cloned from human epithelial cells and plays a crucial role as a metalloproteinase that processes tumor necrosis factor-alpha (TNF-α), a significant proinflammatory cytokine. ADAM17 antibodies are important research tools because ADAM17 is upregulated in numerous cancer types where it activates multiple signaling pathways, particularly EGFR/ErbB pathways. These antibodies allow researchers to study ADAM17's role in cancer progression and potentially develop therapeutic interventions. The metalloproteinase is also implicated in mechanisms of resistance to targeted anti-EGFR therapies, making anti-ADAM17 antibodies valuable for investigating cancer drug resistance mechanisms .

How do researchers validate the specificity of anti-ADAM17 antibodies?

Validating antibody specificity typically involves multiple complementary approaches:

• Cross-reactivity testing with structurally related proteins, particularly other ADAM family members like ADAM10 and ADAM19, using ELISA-based screening methods

• Testing reactivity against both human and mouse ADAM17 ectodomains to confirm species cross-reactivity

• Comparing binding affinity to purified recombinant ADAM17 versus cell lysates lacking ADAM17 expression

• Using cell lines with ADAM17 knockdown or knockout as negative controls

• Performing Western blot analysis to confirm that the antibody detects a protein of the expected molecular weight

For example, researchers developing the D8P1C1 anti-ADAM17 monoclonal antibody confirmed its specificity by demonstrating that it bound to ADAM17 but not to closely related ADAM family members ADAM10 or ADAM19 .

What is the structure of ADAM17 that antibodies target?

The ADAM17 ectodomain (ECD) consists of three major domains: the metalloprotease (MP) domain, the disintegrin (D) domain, and the cysteine-rich (C) domain. During protein maturation, the prodomain is cleaved during secretion. Structural analysis of the mature ADAM17 ECD (amino acid residues 215-655) has shown that it exists as a monomer with a native molecular weight of approximately 65 kDa. Different antibodies may target different domains within the ADAM17 structure, which can affect their functional properties. For instance, the D8P1C1 antibody specifically binds to the ADAM17 protease domain as revealed by negative staining electron microscopy, consistent with its ability to inhibit ADAM17 catalytic activity .

What techniques are used to characterize the binding properties of anti-ADAM17 antibodies?

Several complementary techniques are employed to thoroughly characterize anti-ADAM17 antibody binding properties:

• ELISA assays: To determine binding specificity, cross-reactivity, and relative affinity

• Surface Plasmon Resonance (SPR): For precise measurement of association and dissociation rates (kon and koff), and equilibrium dissociation constant (Kd)

• Cell-based ELISA: To assess binding to native ADAM17 expressed on cancer cell surfaces

• Negative staining electron microscopy: To visualize antibody binding to specific domains of ADAM17

• Competitive binding assays: To determine if multiple antibodies bind to overlapping epitopes

• Epitope mapping: Using truncated ADAM17 constructs or peptide arrays to identify the specific binding region

For the D8P1C1 anti-ADAM17 antibody, researchers used cellular ELISA assays to gauge its binding to ADAM17 expressed on various cancer cell lines, including breast, ovarian, colon, glioma, and adenocarcinoma lines. They also compared its binding to HEK293 cells transfected with full-length human ADAM17 versus untransfected HEK293 cells .

What methodologies are used to generate high-affinity anti-ADAM17 monoclonal antibodies?

The development of high-affinity anti-ADAM17 antibodies typically follows this methodological sequence:

• Antigen preparation: Expression and purification of recombinant ADAM17 ectodomain

• Antibody library generation: Creation of phage-displayed Fab libraries using carefully selected primers that match conserved regions of heavy and light chains

• Selection: Multiple rounds of binding and elution to enrich for ADAM17-specific binders

• Reformatting: Conversion of selected Fabs to complete IgG molecules

• Affinity maturation: Targeted mutagenesis of the variable regions followed by screening for improved binding

• Functional screening: Testing for inhibitory activity against ADAM17 in enzyme assays

• Cell-based validation: Confirming activity in relevant cancer cell lines

This approach was used to develop the D8P1C1 antibody, which was initially selected as a Fab (D8), then reformatted to a human IgG1 framework, and finally affinity-matured to improve binding. The resulting D8P1C1 antibody had a 5-10 fold improvement in IC50 values compared to the parental D8 clone .

How do researchers assess the functional activity of anti-ADAM17 antibodies?

Functional activity assessment involves multiple complementary approaches:

These functional assessments help determine whether an anti-ADAM17 antibody merely binds to the target or actually inhibits its biological function, which is crucial for therapeutic potential .

What is the mechanism by which D8P1C1 anti-ADAM17 antibody inhibits cancer cell proliferation?

The D8P1C1 anti-ADAM17 monoclonal antibody exerts its anti-proliferative effect through several mechanistic pathways:

• Direct enzymatic inhibition: D8P1C1 binds to the protease domain of ADAM17, directly inhibiting its catalytic activity and preventing substrate cleavage

• Disruption of EGFR signaling: By inhibiting ADAM17, D8P1C1 blocks the shedding of EGFR ligands like TGF-alpha, which are critical proliferative signals in many cancers

• Cancer-selective targeting: D8P1C1 preferentially recognizes ADAM17 expressed on cancer cells, potentially due to cancer-specific conformational changes or post-translational modifications of ADAM17

• Inhibition of downstream pathway activation: By preventing EGFR ligand release, the antibody reduces activation of downstream signaling cascades that promote cell proliferation

This multi-faceted mechanism likely explains why D8P1C1 shows efficacy across various EGFR-overexpressing cancer cell lines including triple-negative breast cancer, ovarian, glioma, colon, and lung cancer cell lines .

What is the clinical significance of detecting anti-AGO1 antibodies in patients?

Anti-AGO1 (Argonaute 1) antibodies have emerged as potential biomarkers of autoimmunity in neurological disorders, particularly in a subset of sensory neuronopathy (SNN) cases. The clinical significance of detecting these antibodies includes:

• Improved diagnostic precision: Anti-AGO1 antibodies occur significantly more frequently in SNN (12.9%) compared to non-SNN neuropathies (3.7%), other autoimmune diseases (5.8%), and are absent in healthy controls

• Disease severity correlation: Patients with anti-AGO1 antibody-positive SNN exhibit more severe clinical manifestations compared to antibody-negative SNN cases (SNN score: 12.2 vs 11.0, p=0.004)

• Treatment response prediction: Anti-AGO1 antibody positivity is a significant predictor of response to immunomodulatory treatments (54% vs 16%, p=0.02), particularly to intravenous immunoglobulins (IVIg)

• Therapeutic decision guidance: Detection of anti-AGO1 antibodies may help identify patients who would benefit from specific immunotherapies, especially IVIg

Multivariate logistic regression analysis adjusted for potential confounders showed that anti-AGO1 antibody positivity was the only significant predictor of response to treatment (OR 4.93, 95% CI 1.10-22.24, p=0.03), underscoring its value as a clinical biomarker .

What methodologies are used to detect and characterize anti-AGO1 antibodies in patient samples?

Researchers employ several complementary techniques to detect and characterize anti-AGO1 antibodies:

• ELISA: The primary screening method used to detect anti-AGO1 antibodies in patient sera, offering quantitative results and high throughput capability

• Antibody titer determination: Serial dilution studies to quantify antibody levels, with titers in positive patients ranging from 1:100 to 1:100,000

• IgG subclass analysis: Specialized immunoassays to determine which IgG subclasses (IgG1, IgG2, IgG3, IgG4) predominate, with findings showing anti-AGO1 antibodies are mainly IgG1

• Epitope characterization: Tests to determine whether antibodies recognize conformational or linear epitopes, with 65% of anti-AGO1 antibody-positive SNN patients having antibodies that recognize conformational epitopes

• Cross-reactivity studies: Assays to evaluate potential binding to other Argonaute family proteins or related molecules

These methodological approaches help researchers not only detect the presence of antibodies but also characterize their properties, which may have implications for understanding disease mechanisms and developing targeted therapies .

How can researchers correlate anti-AGO1 antibody characteristics with clinical outcomes?

To establish meaningful correlations between anti-AGO1 antibody characteristics and clinical outcomes, researchers should implement the following methodological approach:

• Comprehensive clinical characterization:

  • Utilize standardized clinical assessment tools (e.g., SNN score)

  • Document detailed neurological examinations

  • Perform nerve conduction studies and other relevant diagnostics

  • Record treatment history and response metrics

• Antibody profile analysis:

  • Measure antibody titers using standardized dilution series

  • Determine IgG subclass distribution (IgG1-4)

  • Characterize epitope specificity (conformational vs. linear)

  • Assess functional effects of antibodies in vitro

• Statistical correlation:

  • Apply multivariate logistic regression to adjust for confounding factors

  • Calculate odds ratios with confidence intervals for treatment response

  • Perform longitudinal analyses to track changes in antibody characteristics and clinical status over time

In the research with anti-AGO1 antibodies, this approach revealed that antibody positivity was associated with more severe disease and better response to IVIg treatment. The response rate to immunomodulatory treatments was significantly higher in anti-AGO1 antibody-positive patients (54%) compared to antibody-negative patients (16%, p=0.02) .

What controls should be included when validating a new anti-ADAM17 antibody?

Rigorous validation of anti-ADAM17 antibodies requires comprehensive control strategies:

• Positive controls:

  • Recombinant ADAM17 protein at known concentrations

  • Cell lines with confirmed high ADAM17 expression (e.g., MDA-MB-231)

  • HEK293 cells transfected with full-length human ADAM17

• Negative controls:

  • Closely related proteins (ADAM10, ADAM19) to confirm specificity

  • Cell lines with ADAM17 knockdown or knockout

  • Untransfected HEK293 cells (for comparison with ADAM17-transfected cells)

• Antibody controls:

  • Isotype-matched irrelevant antibody

  • Previously validated anti-ADAM17 antibodies (e.g., MED13622)

  • Concentration gradients to establish dose-response relationships

• Functional controls:

  • Known ADAM17 inhibitors (e.g., small molecule inhibitors)

  • Substrates with confirmed ADAM17 specificity

  • Mutant ADAM17 with altered catalytic activity

Including these controls ensures that binding specificity, selectivity, sensitivity, and functional activity can be rigorously assessed, as was done in the development and characterization of the D8P1C1 antibody .

How should researchers design experiments to assess anti-ADAM17 antibody efficacy in cancer models?

A comprehensive experimental design to evaluate anti-ADAM17 antibody efficacy in cancer models should include:

• In vitro screening cascade:

  • Enzyme inhibition assays using purified ADAM17 and fluorogenic substrates

  • Cell-based ELISA to confirm binding to native ADAM17 on cancer cells

  • Cell proliferation assays across multiple cancer cell lines with varying ADAM17 and EGFR expression levels

  • Analysis of downstream signaling pathway inhibition (Western blot, phospho-protein arrays)

  • Migration and invasion assays to assess effects on cancer cell motility

• In vivo efficacy studies:

  • Selection of appropriate xenograft models (e.g., triple-negative breast cancer, ovarian cancer)

  • Determination of optimal dosing schedule

  • Measurement of tumor volume over time

  • Analysis of pharmacokinetics and tissue distribution of antibody

  • Examination of tumor tissue for ADAM17 inhibition markers

• Combination therapy assessment:

  • Testing with standard chemotherapeutics

  • Evaluation with other targeted therapies, especially EGFR inhibitors

  • Analysis of potential synergistic effects

This approach was partially demonstrated in studies with D8P1C1, which showed 78% tumor growth inhibition in triple-negative breast cancer models and 45% inhibition in ovarian cancer models .

What are the key considerations when using anti-AGO1 antibodies as diagnostic or prognostic tools?

When implementing anti-AGO1 antibodies as diagnostic or prognostic tools in clinical research, several key considerations must be addressed:

• Assay standardization:

  • Establish standard reference materials and calibrators

  • Determine optimal cutoff values for positivity

  • Implement quality control procedures

  • Ensure reproducibility across different laboratories

• Patient selection and stratification:

  • Clearly define inclusion/exclusion criteria

  • Consider disease duration and previous treatments

  • Account for comorbidities and concomitant medications

  • Stratify patients based on clinical characteristics

• Interpretation guidelines:

  • Establish titer thresholds that correlate with clinical outcomes

  • Consider IgG subclass information in the interpretation

  • Evaluate the significance of conformational versus linear epitope recognition

  • Incorporate results into comprehensive clinical assessment

• Follow-up testing protocol:

  • Determine optimal intervals for repeated testing

  • Establish criteria for significant titer changes

  • Correlate antibody level changes with clinical response

  • Develop algorithms for treatment modification based on antibody status

Research has shown that anti-AGO1 antibody positivity predicts response to immunomodulatory treatments with an odds ratio of 4.93 (95% CI 1.10-22.24, p=0.03), highlighting the potential value of these antibodies as clinical tools .

What challenges exist in developing highly specific antibodies against ADAM17?

Developing highly specific antibodies against ADAM17 presents several technical challenges:

• Structural homology with related proteins: ADAM17 shares significant sequence and structural similarity with other ADAM family members, particularly ADAM10, making specificity difficult to achieve. Researchers address this by using phage display libraries and targeted mutagenesis to identify antibodies that bind to unique epitopes on ADAM17.

• Conformational complexity: The native conformation of ADAM17 on cell surfaces may differ from recombinant proteins used for immunization. To overcome this, researchers employ cell-based screening methods to identify antibodies that recognize the native conformation of ADAM17.

• Post-translational modifications: Different glycosylation patterns and other modifications may affect antibody binding. Researchers address this by testing antibody binding to ADAM17 from various cellular sources.

• Active site accessibility: The catalytic site of ADAM17 may be difficult to target with antibodies due to steric hindrance. Structural analysis, such as negative staining electron microscopy used with D8P1C1, helps identify antibodies that can access functionally important regions.

• Species cross-reactivity: Developing antibodies that recognize both human and mouse ADAM17 is challenging but important for translational research. Careful epitope selection and screening against multiple species variants can help overcome this challenge .

How can researchers optimize anti-ADAM17 antibodies for specific research applications?

Optimizing anti-ADAM17 antibodies for specific research applications requires tailored approaches:

• For imaging applications:

  • Conjugate antibodies with appropriate fluorophores or contrast agents

  • Validate that conjugation doesn't affect binding properties

  • Optimize antibody concentration and incubation conditions

  • Confirm specificity in relevant tissue types

• For therapeutic development:

  • Humanize or fully human antibodies to reduce immunogenicity

  • Engineer Fc regions for desired effector functions or extended half-life

  • Consider antibody-drug conjugates for enhanced potency

  • Optimize formulation for stability and delivery

• For mechanistic studies:

  • Develop domain-specific antibodies targeting different regions of ADAM17

  • Create function-blocking versus non-blocking antibodies for comparative studies

  • Generate antibodies recognizing active versus inactive conformations

  • Develop antibodies against specific post-translational modifications

• For diagnostic applications:

  • Optimize sensitivity and specificity for the intended sample type

  • Validate in diverse patient populations

  • Ensure compatibility with standard clinical laboratory procedures

  • Establish appropriate reference ranges and cutoff values

Researchers developing D8P1C1 optimized it through affinity maturation, achieving binding affinities in the picomolar range (Kds of 50-80 pM), representing a 10-fold improvement over parental clones .

What factors influence the reproducibility of experimental results when using anti-AGO1 antibodies?

Several critical factors can impact the reproducibility of experiments utilizing anti-AGO1 antibodies:

• Patient sample handling:

  • Storage conditions and freeze-thaw cycles of serum samples

  • Standardized collection protocols (timing, processing methods)

  • Sample pre-treatment procedures

  • Use of preservatives or stabilizers

• Assay technical variables:

  • Batch-to-batch variation in recombinant AGO1 protein

  • Plate coating conditions and blocking reagents

  • Incubation times and temperatures

  • Detection system sensitivity and calibration

• Cutoff determination:

  • Statistical approach used to define positivity

  • Reference population selection

  • Inclusion of borderline positive controls

  • Inter-laboratory validation

• Clinical variables:

  • Timing of sample collection relative to disease course

  • Prior immunosuppressive treatments

  • Presence of other autoantibodies

  • Comorbid conditions affecting immune status

• Analytical considerations:

  • Standardized reporting of titers

  • Consistent IgG subclass analysis methodology

  • Uniform criteria for epitope classification

  • Appropriate statistical methods for small sample sizes

In the study of anti-AGO1 antibodies in sensory neuronopathy, researchers employed a retrospective multicentric case/control design with standardized ELISA screening of 132 SNN patients, 301 non-SNN neuropathy patients, 274 autoimmune disease patients, and 116 healthy controls to ensure robust and reproducible results .

What emerging applications exist for anti-ADAM17 antibodies beyond cancer research?

Anti-ADAM17 antibodies show promise for several emerging research areas beyond cancer:

• Inflammatory disorders: Given ADAM17's role in processing TNF-α and other inflammatory mediators, anti-ADAM17 antibodies could provide more targeted approaches for conditions like rheumatoid arthritis, inflammatory bowel disease, and psoriasis compared to global TNF-α inhibition.

• Neurodegenerative diseases: ADAM17 mediates shedding of neuroinflammatory signals and amyloid precursor protein processing, making it relevant to Alzheimer's disease and other neurodegenerative conditions where selective inhibition might be beneficial.

• Cardiovascular research: ADAM17 influences vascular remodeling, atherosclerosis progression, and heart failure development through its sheddase activity on multiple substrates, offering potential therapeutic targets for cardiovascular conditions.

• Fibrotic disorders: ADAM17 regulates growth factor signaling implicated in fibrosis of lung, liver, and kidney, suggesting applications for anti-ADAM17 antibodies in studying and potentially treating these pathologies.

• Infectious disease: ADAM17 mediates ACE2 shedding relevant to SARS-CoV-2 infection, opening avenues for using anti-ADAM17 antibodies to study viral entry mechanisms and potential therapeutic approaches.

Developing application-specific anti-ADAM17 antibodies with tailored characteristics would expand their utility beyond the cancer research applications demonstrated with antibodies like D8P1C1 .

How might advanced antibody engineering enhance the research applications of anti-ADAM17 antibodies?

Advanced antibody engineering offers several opportunities to enhance anti-ADAM17 antibody utility:

• Bispecific antibodies: Engineering antibodies that simultaneously target ADAM17 and EGFR or other relevant targets could enhance specificity for cancer cells and potentially improve therapeutic efficacy.

• Intrabodies: Developing cell-penetrating anti-ADAM17 antibodies or antibody fragments that can access intracellular pools of ADAM17 would enable new research into its trafficking and maturation.

• Conformation-specific antibodies: Engineering antibodies that selectively recognize active versus inactive ADAM17 conformations would provide valuable tools for studying activation mechanisms and identifying active enzyme pools.

• Domain-selective inhibitors: Creating antibodies that block shedding of specific ADAM17 substrates while permitting others would allow more nuanced research into substrate-specific functions.

• Antibody fragments: Developing smaller antibody formats (Fab, scFv, nanobodies) with enhanced tissue penetration could improve in vivo imaging applications and access to ADAM17 in various tissue compartments.

• Responsive antibodies: Creating antibodies with activity modulated by specific conditions (pH, protease presence, etc.) could enable context-dependent inhibition for studying ADAM17 in complex microenvironments.

These engineering approaches would build upon the foundation established with antibodies like D8P1C1 and D5P2A11, expanding the toolkit available for ADAM17 research .

What are the prospects for developing anti-AGO1 antibodies as therapeutic agents?

The development of anti-AGO1 antibodies as therapeutic agents represents an emerging frontier with several considerations:

• Therapeutic target validation:

  • Since anti-AGO1 antibody-positive SNN patients respond better to immunomodulatory treatments (especially IVIg), neutralizing circulating anti-AGO1 antibodies could potentially reduce disease severity

  • Further research is needed to establish the pathogenic role of these antibodies versus their utility as biomarkers

• Potential therapeutic approaches:

  • Development of decoy AGO1 antigens to neutralize circulating antibodies

  • AGO1-specific immunoadsorption columns for therapeutic apheresis

  • B-cell targeted therapies to reduce anti-AGO1 antibody production

  • Peptide therapeutics that block the binding of anti-AGO1 antibodies to their target

• Challenges and considerations:

  • Need for better understanding of the specific epitopes recognized by pathogenic anti-AGO1 antibodies

  • Potential functional redundancy among AGO family proteins

  • Requirement for highly selective targeting to avoid disrupting normal AGO1 function

  • Necessity for sensitive monitoring of anti-AGO1 antibody levels during treatment

• Research priorities:

  • Animal models of anti-AGO1 antibody-mediated neurological disease

  • Mechanistic studies of how anti-AGO1 antibodies cause neuronal injury

  • Biomarker studies correlating antibody characteristics with treatment response

  • Proof-of-concept studies with targeted immunotherapies

The finding that anti-AGO1 antibody positivity is associated with better response to IVIg (OR 4.93, 95% CI 1.10-22.24) provides rationale for developing more targeted therapeutic approaches for this subset of patients with sensory neuronopathy .